History

This study analyzed the effectiveness and safety of perampanel as a treatment for epilepsy in children aged < 36 months. A randomized block parallel controlled trial was conducted on 240 children with epilepsy, with 120 receiving perampanel, 60 receiving clonazepam, and 60 receiving levetiracetam. The results of this study showed the efficacy of perampanel in reducing the symptoms and signs of epilepsy, minimizing the need for hospitalization, and decreasing systemic and neurotoxic side effects and adverse reactions in comparison to clonazepam and levetiracetam. This study concluded that perampanel is an effective and safe drug for young children with epilepsy and should be considered a treatment option. The analysis of symptoms and signs of epilepsy in children under 15 months of age within 12 months of starting treatment showed that the perampanel group had significantly fewer incidences of jerking movements of the arms and legs, loss of consciousness, excessive abnormal crying, and repetitive abnormal movement of the eyes than the clonazepam and levetiracetam groups. Similarly, in children between 16 and 36 months of age, the perampanel group showed significantly fewer incidences of staring and jerking movements of the arms and legs than the clonazepam and levetiracetam groups. These findings suggest that perampanel may be a more effective treatment option for children with epilepsy in this age range. The study found that the use of perampanel (fyocampa) was associated with a significant decrease in systemic and neurotoxic side effects compared with clonazepam and levetiracetam in children under 36 months of age. There was also a more significant reduction in symptoms and signs of epilepsy with perampanel (fyocampa) than with the other two medications. These findings suggest that perampanel (fyocampa) may be a safer and more effective treatment option for young children with epilepsy.